Editas Medicine, Inc.
CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
Last updated:
Abstract:
CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
Status:
Grant
Type:
Utility
Filling date:
19 Feb 2019
Issue date:
8 Mar 2022